比较弥漫性糖尿病性黄斑水肿患者玻璃体内曲安奈德治疗与玻璃体内曲安奈德联合格栅样激光治疗的效果。

Comparison of intravitreal triamcinolone treatment and intravitreal triamcinolone with grid laser treatment in patients with diffuse diabetic macular edema.

机构信息

Department of Ophthalmology, Faculty of Medicine, Çanakkale Onsekiz Mart University, Çanakkale, Turkey.

Department of Ophthalmology, Faculty of Medicine, Gazi University, Ankara, Turkey.

出版信息

Balkan Med J. 2012 Jun;29(2):166-9. doi: 10.5152/balkanmedj.2012.008. Epub 2012 Jun 1.

DOI:10.5152/balkanmedj.2012.008

PMID:25206988

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4115852/

Abstract

OBJECTIVE

To compare the efficacy of intravitreal triamcinolone acetonide (IVTA) and IVTA plus macular laser grid photocoagulation therapy in diffuse diabetic macular edema (DME).

MATERIAL AND METHODS

Sixteen patients affected by diffuse DME were retrospectively evaulated. Patients were divided into two groups: control group (IVTA injection) and laser group (IVTA plus grid laser). Main outcomes were best corrected visual aquity (BCVA) and central macular thickness (CMT) at the 3(rd) and 6(th) months of treatment. IVTA associated complications and reinjection necessity were assessed.

RESULTS

Our study comprised 18 eyes of 16 patients. The baseline BCVA and CMT were 0.93±0.45 and 530±136μm for the control and 1.02±0.52 and 509±177μm for the laser group respectively. Posttreatment BCVA at the 3(rd) and 6(th) month were 0.73±0.4 and 0.75±0.45 for control and 0.98±0.44 and 1.04±0.4 for laser group respectively (p>0.05 for all). CMT values at the 3(rd) and 6(th) months were 260±174μm (p=0.008) and 362±163 μm (p=0.05) for control and 331±161μm (p=0.05) and 388±215 μm (p>0.05) for laser groups. 55% of control and 66% of laser groups needed reinjection with an avarage of 7±4 months after the first injection. 22% cataract progression and 33% intraocular pressure elevation were noted.

CONCLUSION

Macular grid laser photocoagulation after IVTA does not have beneficial effects for diffuse DME.

摘要

目的

比较玻璃体内曲安奈德（IVTA）和 IVTA 联合黄斑激光格栅光凝治疗弥漫性糖尿病性黄斑水肿（DME）的疗效。

材料和方法

回顾性评估了 16 例弥漫性 DME 患者。患者分为两组：对照组（IVTA 注射）和激光组（IVTA 联合格栅激光）。主要结局是治疗第 3 个月和第 6 个月的最佳矫正视力（BCVA）和中心黄斑厚度（CMT）。评估 IVTA 相关并发症和再注射的必要性。

结果

本研究包括 16 例患者的 18 只眼。对照组和激光组的基线 BCVA 和 CMT 分别为 0.93±0.45 和 530±136μm，1.02±0.52 和 509±177μm。治疗第 3 个月和第 6 个月的 BCVA 分别为 0.73±0.4 和 0.75±0.45，对照组为 0.98±0.44 和 1.04±0.4 激光组（所有 p>0.05）。治疗第 3 个月和第 6 个月的 CMT 值分别为 260±174μm（p=0.008）和 362±163μm（p=0.05），对照组为 331±161μm（p=0.05）和 388±215μm（p>0.05）激光组。对照组和激光组分别有 55%和 66%的患者需要在第一次注射后 7±4 个月进行再注射。观察到 22%的白内障进展和 33%的眼压升高。